Karyopharm Therapeutics, Inc. (KPTI)
6.75
-0.44
(-6.12%)
USD |
NASDAQ |
Jan 15, 13:13
Karyopharm Therapeutics SG&A Expense (TTM): 109.63M for Sept. 30, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Bruker Corp. | 946.60M |
| TG Therapeutics, Inc. | 208.25M |
| Actinium Pharmaceuticals, Inc. | 15.79M |
| Axsome Therapeutics, Inc. | 514.57M |
| Krystal Biotech, Inc. | 136.75M |